144 related articles for article (PubMed ID: 37985356)
1. Characteristics of clinical trials of new oncology drugs approved in China.
Yang J; Yang J; Hu YJ
Cancer; 2024 Mar; 130(5):671-682. PubMed ID: 37985356
[TBL] [Abstract][Full Text] [Related]
2. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical trial designs for novel anticancer drugs in China: A cohort study of drugs approved between 2015 and 2021.
Luo X; Guo Q; Du X; Huang L; Chow SC; Yang Y
Drug Discov Today; 2023 Jun; 28(6):103578. PubMed ID: 37004982
[TBL] [Abstract][Full Text] [Related]
6. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
[TBL] [Abstract][Full Text] [Related]
7. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan.
Maeda H; Shingai R; Takeda K; Hara A; Murai Y; Ofuchi M
JAMA Netw Open; 2023 Apr; 6(4):e238875. PubMed ID: 37115550
[TBL] [Abstract][Full Text] [Related]
9. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
Hsiue EH; Moore TJ; Alexander GC
Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
[TBL] [Abstract][Full Text] [Related]
10. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
Maeda H; Kurokawa T
Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
[TBL] [Abstract][Full Text] [Related]
11. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
Apolone G; Joppi R; Bertele' V; Garattini S
Br J Cancer; 2005 Sep; 93(5):504-9. PubMed ID: 16136026
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
Gyawali B; Hey SP; Kesselheim AS
JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
14. Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs.
Hirai T; Suzuki A; Yamori T; Matsuura M
Invest New Drugs; 2022 Feb; 40(1):142-150. PubMed ID: 34417913
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
Hilal T; Sonbol MB; Prasad V
JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
18. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.
Kim MS; Xu A; Haslam A; Prasad V
Int J Cancer; 2022 Jun; 150(11):1905-1910. PubMed ID: 35182072
[TBL] [Abstract][Full Text] [Related]
19. [Progress on clinical trials of cancer drugs in China, 2020].
Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488
[No Abstract] [Full Text] [Related]
20. Bridging the new drug access gap between China and the United States and its related policies.
Zhu X; Chen Y
Front Pharmacol; 2023; 14():1296737. PubMed ID: 38259295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
